[Central effects of some adreno- and-or sympatholytic substances. 3. Ptosis, catalepsy, antagonism with respect to apomorphine and amphetamine].
D000818:Animals; D001058:Apomorphine / Q000037:antagonists & inhibitors*; D001763:Blepharoptosis / Q000139:chemically induced*; D001949:Bretylium Compounds / Q000494:pharmacology*; D002375:Catalepsy / Q000139:chemically induced*; D002490:Central Nervous System / Q000187:drug effects; D002746:Chlorpromazine / Q000494:pharmacology*; D003913:Dextroamphetamine / Q000037:antagonists & inhibitors* / Q000633:toxicity; D003983:Dibenzylchlorethamine / Q000494:pharmacology*; D004878:Ergotamine / Q000494:pharmacology*; D005143:Eyelids / Q000187:drug effects; D006145:Guanethidine / Q000494:pharmacology*; D006801:Humans; D008750:Methyldopa / Q000494:pharmacology*; D051379:Mice; D010643:Phenoxybenzamine / Q000494:pharmacology*; D010646:Phentolamine / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology*; D051381:Rats; D014149:Tranquilizing Agents / Q000494:pharmacology*; D015016:Yohimbine / Q000494:pharmacology*
D001949:Bretylium Compounds; D014149:Tranquilizing Agents; D010643:Phenoxybenzamine; D015016:Yohimbine; D003983:Dibenzylchlorethamine; D008750:Methyldopa; D011433:Propranolol; D001058:Apomorphine; D004878:Ergotamine; D003913:Dextroamphetamine; D002746:Chlorpromazine; D010646:Phentolamine; D006145:Guanethidine
Effets centraux de quelques substances adréno- et-ou sympatholytiques. 3. Ptosis, catalepsie, antagonisme vis-à-vis de l'apomorphine et de l'amphétamine.